Company profile: NBE Therapeutics
1.1 - Company Overview
Company description
- Provider of oncology therapies based on proprietary antibody-drug conjugates, including SMAC-Technology enzymatic conjugation for site-specific ADC manufacturing, Transpo-mAb mammalian cell display antibody discovery, a PNU-159682 anthracycline toxin payload platform, immune-oncology ADCs that activate CD8 cytotoxic T cells, and the ROR1-targeting NBE-002 candidate.
Products and services
- Immune Oncology: Next-generation ADCs that induce a long-lasting anti-tumor immunity by activating tumor-antigen specific CD8 positive cytotoxic T cells, delivering immune-stimulatory activity against cancer
- SMAC-Technology™: An enzymatic conjugation platform enabling site-specific attachment of drugs to monoclonal antibodies for the manufacturing of antibody-drug conjugates
- PNU anthracycline payload: A highly potent anthracycline-based toxin platform for ADCs, based on PNU-159682, offering significant potency against cancer cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NBE Therapeutics
OnKure Therapeutics
HQ: United States
Website
- Description: Provider of next-generation oncology precision medicines targeting validated cancer drivers, developed by a clinical-stage biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnKure Therapeutics company profile →
Inanovate
HQ: United States
Website
- Description: Provider of multiplexed protein quantification and longitudinal assay screening technologies for detecting and measuring multiple proteins, including the Bio-ID real-time platform (high sensitivity confocal imaging and microfluidics) and LAS time-resolved fluorescent assays. Also offers a breast cancer blood test to improve mammography accuracy and detect recurrence, Bio-ID services, an alliance program for LAS assays, and the i-Slide protein microarray substrate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inanovate company profile →
Deciphera Pharmaceuticals
HQ: United States
Website
- Description: Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deciphera Pharmaceuticals company profile →
QT Imaging
HQ: United States
Website
- Description: Provider of breast imaging services via tomographic transmission ultrasound, offering non-invasive 3D imaging without contrast agents or radiation. Products include the Breast Acoustic CT System, QTscan, and an AI-enabled diagnostic platform leveraging transmission and reflection modalities, plus QT Imaging 3D technology for tissue-specific microanatomy and 3D Acoustic CT for potential whole-body diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QT Imaging company profile →
ALX Oncology
HQ: United States
Website
- Description: Provider of preclinical-stage immuno-oncology therapies for cancer, including Evorpacept (ALX148), a next-generation CD47 blocking therapeutic with high affinity for CD47 and designed to avoid hematologic toxicities, used in combination with anti-cancer agents to enhance immune activation and treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ALX Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NBE Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NBE Therapeutics
2.2 - Growth funds investing in similar companies to NBE Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NBE Therapeutics
4.2 - Public trading comparable groups for NBE Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →